Literature DB >> 2493435

Stage I and II non-Hodgkin's lymphomas: long-term results of radiation therapy.

S Reddy1, V S Saxena, E V Pellettiere, F R Hendrickson.   

Abstract

One hundred and sixteen patients with Stages I and II non-Hodgkin's lymphomas were treated with curative radiotherapy between 1964 and 1977. The initial biopsy material was classified according to the criteria of Rappaport et al. All the patients except six were followed for a minimum of 8 years or until death with ninety-two patients having been followed for 10 or more years. Histological pattern was found to be an important prognostic factor with better survival in patients with nodular histology. There were forty-three patients with an initial involvement of an extra-nodal site forming 37% of the total group. Stage I extra-nodal lymphomas had a survival and recurrence-free survival rates of 80% and 74% respectively, similar to those of nodal lymphomas. Stage II patients in both groups did worse than those with Stage I. Survival rates and disease-free survival rates for different histologic types and their pattern of recurrence are presented.

Entities:  

Mesh:

Year:  1989        PMID: 2493435     DOI: 10.1016/0360-3016(89)90486-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  Primary lymphoma of the penis with rationale of treatment.

Authors:  R D Carter; R Smith; H D Alpern; B M Healey
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

2.  Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma.

Authors:  G M Jeffery; G M Mead; J M Whitehouse; R D Ryall
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

3.  Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma.

Authors:  J Spicer; P Smith; K Maclennan; P Hoskin; B Hancock; D Linch; R Pettengell
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.